Nurix Therapeutics, Inc. (NRIX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$14.84-6.96%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · NRIX
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Nov 2025 | Nov 2024 | Nov 2023 | Nov 2022 | Nov 2021 | Nov 2020 | |
|---|---|---|---|---|---|---|---|
| Revenues | |||||||
| Revenues | 701.9 | 84.0 | 54.5 | 77.0 | 38.6 | 29.8 | 17.8 |
| Total Revenues | — | — | — | 77.0 | 38.6 | 29.8 | 17.8 |
| Operating Expenses & Income | |||||||
| R&D Expenses | 334.1 | 316.9 | 221.6 | 189.1 | 184.5 | 116.4 | 66.5 |
| Operating Income | 289.7 | (285.7) | (213.0) | (155.1) | (183.9) | (117.9) | (65.0) |
| Earnings from Continuing Operations | |||||||
| EBT, Incl. Unusual Items | — | (263.7) | (193.3) | (143.9) | (180.4) | (117.1) | (63.8) |
| Income Tax Expense | — | 0.8 | 0.3 | 0.0 | 0.0 | 0.1 | (20.5) |
| Net Income | |||||||
| Net Income | 294.9 | (264.5) | (193.6) | (143.9) | (180.4) | (117.2) | (43.2) |
| Per Share | |||||||
| Basic EPS | 2.64 | (3.05) | (2.88) | (2.65) | (3.71) | (2.73) | — |
| Diluted EPS | 2.54 | (3.05) | (2.88) | (2.65) | (3.71) | (2.73) | — |
| Revenue per Share | 6.04 | — | — | — | — | — | — |
| Dividend per Share | — | — | — | — | — | — | 0.00 |
| Basic Weighted Avg Shares | 111.6 | 86.7 | 67.1 | 54.3 | 48.6 | 42.9 | — |
| Diluted Weighted Avg Shares | 116.2 | 86.7 | 67.1 | 54.3 | 48.6 | 42.9 | — |
| Supplemental | |||||||
| EBITDA | — | (276.9) | (203.7) | (147.5) | (178.5) | (115.1) | (62.8) |
| EBIT | 289.7 | (285.7) | (213.0) | (155.1) | (183.9) | (117.9) | (65.0) |
| Effective Tax Rate | — | — | — | 0.0% | 0.0% | -0.1% | 32.2% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.